You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Litigation Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (D. Del. 2018)

✉ Email this page to a colleague

« Back to Dashboard

AstraZeneca AB v. Mylan Pharmaceuticals Inc. (D. Del. 2018)

Docket	⤷ Sign Up	Date Filed	2018-10-11
Court	District Court, D. Delaware	Date Terminated	2019-11-03
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Parties	MYLAN N.V.
Patents	10,166,247; 7,759,328; 7,967,011; 8,143,239; 8,575,137
Attorneys	Daniel M. Silver
Firms	Perkins Coie LLP
Link to Docket	External link to docket

Small Molecule Drugs cited in AstraZeneca AB v. Mylan Pharmaceuticals Inc.

The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .

Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (D. Del. 2018)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
2019-10-18	156	Opinion - Memorandum Opinion	additional patent to the lawsuit, United States Patent No. 10,166,247 (the "#247 patent"). See…quot;#239 patent"), 8,575,137 (the "#137 patent"), and 7,967,011 (the #011 patent").…of infringing United States Patent Nos. 7,759,328 (the "#328 patent"), 8,143,239 (the 1 …Pharmaceuticals Inc. ("Mylan") and 3M Company for patent infringement. Before me is Mylan's motion …Paragraph IV certifications against the asserted patents. D.I. 41, Ex. B. On August 15, 2018, the FDA sent	External link to document
2019-01-06	20		of U.S. Patent Nos. 7,759,328, 8,143,239, 8,575,137, and 7,967,011 (collectively, the “patents-in-suit…....... 5 B. Venue in Patent Infringement Actions ..........................…..................6 In re Rosuvastatin Calcium Patent Litig., 719 F. Supp. 2d 388 (D. Del. 2010) …INTRODUCTION AND SUMMARY OF ARGUMENT This patent infringement action arises from the filing of ANDA…that these entities will infringe Plaintiffs’ patents in the future. But MLL, Mylan Inc., and Mylan N.V	External link to document
2018-10-11	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,759,328; 8,143,239; 8,575,137…2018 4 November 2019 1:18-cv-01562 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2019-05-31	70	Complaint - Amended	,143,239 ;8,575,137 ;7,967,011 ;10,166,247 . (Silver, Daniel) Modified on 6/4/2019 (fms). (Entered: 05… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,759,328 ;8,143,239…2018 4 November 2019 1:18-cv-01562 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.